Search results
Beyond BCMA-Directed CAR T-Cell Therapy
MedPage Today· 5 days agoAlthough survival rates for patients with multiple myeloma are improving, with a 5-year rate of about 60%, many patients relapse after treatment....
Izokibep Enthesitis Benefit Lacking in Phase 2b/3 PsA Trial
Medscape· 7 days agoThe primary efficacy endpoint was met, but the novel small molecule therapeutic did not reduce...
Why Wall Street Is Chasing Ozempic Wannabes
The Wall Street Journal· 5 days agoHEARD ON THE STREET Gilead Sciences a biotech company focused on treatments for cancer and HIV, isn’t pitching itself as an obesity-drug developer. But...
10 Health Care Stocks Whale Activity In Today's Session - Community Health Sys (NYSE:CYH),...
Benzinga· 6 days agoLoading... Loading... This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga ...
ASCO 2024: How to Best Use New Breast Cancer Data
Medscape· 6 days agoKevin Kalinsky and Sara Hurvitz discuss the results of awaited data in the breast cancer space presented at the 2024 ASCO Annual Meeting.
Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
BioPharma Dive via Yahoo Finance· 4 days agoA medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two...
5 Undervalued Stocks From Morningstar’s New LGBTQ+ Index
Morningstar· 5 days agoDEI is a cornerstone of the “social” pillar of environmental, social, and governance investing,...
Day One targets the growing ADC market with MabCare acquisition
Pharmaceutical Technology via Yahoo Finance· 6 days agoDay One has entered a licensing agreement for MTX-13, now called DAY301, a novel antibody drug...
Glofitamab Regimen Improves Survival in DLBCL
MedPage Today· 6 days agoGranted accelerated approval last year, bispecific antibody passes its confirmatory test
ASCO 2024: Updates on Clinical Trials in Gynecologic Cancers
Medscape· 2 days agoDr Don Dizon highlights new data in gynecologic cancers from the 2024 ASCO Annual Meeting.
